Ocugen-Carisma merger terminated after Ocugen failed to secure $25M investment

Ocugen, Inc.

Carisma terminated Merger Agreement on Sep 16, 2025 because Ocugen obtained less than $25M in commitments for the Concurrent Investment.
Ocugen attributes difficulty to poor market conditions and the tight timeline before Carisma's Nasdaq compliance deadline of Oct 7, 2025.
Ocugen will focus on gene therapies and continue exploring other options for its regenerative cell therapy platform, including NeoCart.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.